Background -Inhaled frusemide exerts a protective effect against bronchoconstriction induced by several indirect stimuli in asthma. This effect could be caused by interference with neural pathways. The effect of inhaled frusemide on bronchoconstriction induced by inhaled bradykinin, which is thought to cause bronchoconstriction via neural mechanisms, was studied and compared with the effects of adenosine 5'-monophosphate (AMP) which probably produces its airway effects by augmenting mast cell mediator release and interfering with neural pathways. Methods -Patients first underwent AMP and bradykinin challenges. They were then studied in a randomised, placebo controlled, double blind fashion. Ten atopic asthmatic subjects, studied on four days, were pretreated with inhaled frusemide (40 mg) or placebo for 10 minutes, five minutes before challenge with increasing concentrations of nebulised AMP or bradykinin. 
mechanism of action for frusemide. The loop diuretic frusemide, when administered by inhalation, protects the asthmatic airways against various bronchoconstrictor stimuli such as allergen,' ultrasonically nebulised distilled water,2 exercise,3 cold air,4 sodium metabisulphite,5 and adenosine 5'-monophosphate (AMP).6 The mechanisms underlying the protective effects of this drug against these different forms of provocation in asthma are not understood. Based on structure-activity studies with other loop diuretics the protective efficacy of inhaled frusemide is thought not to involve the ATP-dependent Na+-K+-Cl cotransport.7 Other possibilities include the capacity of this drug to locally generate prostaglandin E2 (PGE2) with functional antagonistic effects,89 a suppressive action on airway mast cells,'0 and inhibition of neural pathways. In support of an effect on airway nerves, frusemide has been shown to inhibit the cough response induced by low chloride aerosols," and both inhaled frusemide and bumetanide produce dose-dependent inhibition of the contractile response of airways smooth muscle induced by stimulation of cholinergic and non-cholinergic non-adrenergic nerves independent of cyclooxygenase production in guinea pigs. '2 Bradykinin is produced by the action of kallikreins on high molecular weight kininogen."3 Inhaled bradykinin induces bronchoconstriction in a dose-dependent fashion in asthmatic subjects '4 . In vivo structure-activity studies have suggested that bradykinin produces bronchoconstriction by stimulating 162 receptors. ' The effect of inhaled frusemide on bradykinin-induced bronchoconstriction has not been reported. In this study we have investigated the effect of inhaled frusemide against bronchoconstriction provoked by bradykinin and compared it with that of AMP which probably produces its airway effects by augmenting mast cell mediator release and excitation of neural pathways. We have also assessed the degree of protection afforded by frusemide against both stimuli as, if a similar degree of protection was found, this would support a common mechanism of action for this drug in the airways.
Methods

SUBJECTS
Ten asthmatic subjects (eight males) with a mean (SE) age 25-5 (2 4) years participated in the study. All subjects were non-smokers with atopic asthma as judged by at least one weal > 3 mm on skin prick testing with Dermatophagoides pteronyssinus, house dust, mixed grass pollen, cat fur, and feathers (Bencard, Brentford, Middlesex, UK The study was divided into two phases.
Phase 1
Subjects attended the laboratory on three separate occasions at least 72 hours apart to undertake concentration response studies with inhaled AMP, bradykinin, and histamine in the absence of any drug treatment in order to establish the baseline level of response.
Phase 2
Subjects attended the laboratory on four occasions, separated by at least 72 hours, to undertake concentration response studies with inhaled AMP and bradykinin after nebulised frusemide or matched nebulised vehicle placebo. These were administered in a double blind and random fashion. On each occasion, after 15 minutes rest, three baseline measurements of FEV, were recorded at intervals of three minutes. This was followed by inhalation of nebulised frusemide (10 mg/ml, pH 9, osmolarity 289 mosmol/kg) or matched placebo (pH 9, osmolarity 298 mosmol/kg). The aerosol solutions were generated from a start- imately fivefold protection against bronchoconstriction induced by both AMP and bradykinin. Since these agonists are considered to produce bronchoconstriction by differing mechanisms -bradykinin involving sensory nerve stimulation and tachykinin release, and AMP augmenting mast cell mediator release and, to a lesser extent, via neural stimulationthe mechanism of protection afforded by frusemide is puzzling. Bradykinin (mg/ml) Frusemide is known to produce some of its effect in the kidney by the secondary production of endogenous prostanoids,22 23 
